Details for Patent: 6,689,812

Title:	Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
Abstract:	A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
Inventor(s):	Peet; Malcolm (Sheffield, GB), Vaddadi; Krishna S (Melbourne, AU)
Assignee:	Laxdale Limited (Stirling, GB)
Filing Date:	Dec 14, 2001
Application Number:	10/014,603
Claims:	1. A pharmaceutical preparation comprising EPA in an appropriately assimilable form, wherein of all the fatty acids present in the preparation at least 90% is in the form of EPA, and where less than 5% is in the form of docosahexaenoic acid (DHA), and a drug which acts primarily on neurotransmitter metabolism or receptors, wherein an enhanced effect is obtained. 2. The pharmaceutical preparation of claim 1, wherein of all the fatty acids present in the preparation at least 95% is in the form of EPA. 3. The pharmaceutical preparation of claim 1, wherein of all the fatty acids present in the preparation less than 3% is in the form of docosahexaenoic acid (DHA). 4. The pharmaceutical preparation of claim 1, wherein among the other fatty acids present there are less than 5% of each of AA or DPA-n-3, individually. 5. The pharmaceutical preparation of claim 2, wherein among the other fatty acids present there are less than 3% of each of AA or DPA-n-3, individually. 6. The pharmaceutical preparation of claim 1, wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 10% of the total fatty acids present. 7. The pharmaceutical preparation of claim 3, wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 5% of the total fatty acids present. 8. The pharmaceutical preparation of claim 1, wherein the EPA is in the form of EPA selected from the group consisting of ethyl-EPA, lithium EPA, mono-, di- and triglyceride EPA and any other ester or salt of EPA, and the free acid form of EPA, and other appropriate bioavailable derivative which raises EPA levels within the body. 9. The pharmaceutical preparation of claim 1, wherein the EPA is in the form of a derivative selected from the group consisting of a 2-substituted derivative and other derivatives which reduce the rate of oxidation without impairing its biological activity. 10. The pharmaceutical preparation of claim 1, wherein the drug is clozapine. 11. The pharmaceutical preparation of claim 1, wherein the drug is a typical neuroleptic or an a typical neuroleptic, chlorpromazine, haloperidol, risperidone, olanzapine, sertindole, ziprasidone, zotepine or amisulpiride. 12. The pharmaceutical preparation of claim 11, wherein the a typical neuroleptic or the typical neuroleptic is chlorpromazine, haloperidol, risperidone, olanzapine, sertindole, ziprasidone, zotepine or amisulpiride.